Charles River Laboratories International - CRL Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $256.38
  • Forecasted Upside: 22.25%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.31 (0.63%)

This chart shows the closing price for CRL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Charles River Laboratories International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRL

Analyst Price Target is $256.38
▲ +22.25% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $256.38, with a high forecast of $290.00 and a low forecast of $205.00. The average price target represents a 22.25% upside from the last price of $209.72.

This chart shows the closing price for CRL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Charles River Laboratories International. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2024MizuhoInitiated CoverageNeutral$235.00Low
6/6/2024The Goldman Sachs GroupInitiated CoverageBuy$290.00Low
5/13/2024TD CowenLower TargetHold ➝ Hold$260.00 ➝ $228.00Low
5/10/2024Robert W. BairdLower TargetOutperform ➝ Outperform$282.00 ➝ $270.00Low
3/18/2024ArgusBoost TargetBuy ➝ Buy$240.00 ➝ $290.00Low
2/15/2024Evercore ISIBoost TargetOutperform ➝ Outperform$260.00 ➝ $265.00Low
2/15/2024CitigroupBoost TargetNeutral ➝ Neutral$215.00 ➝ $250.00Low
2/15/2024UBS GroupBoost TargetBuy ➝ Buy$270.00 ➝ $290.00Low
2/15/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$270.00 ➝ $280.00Low
2/15/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$252.00 ➝ $268.00Low
2/15/2024GuggenheimDowngradeBuy ➝ NeutralLow
12/20/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$210.00 ➝ $270.00Low
12/11/2023CitigroupBoost TargetNeutral ➝ Neutral$190.00 ➝ $215.00Low
11/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$220.00 ➝ $205.00Low
11/9/2023UBS GroupLower TargetBuy ➝ Buy$250.00 ➝ $215.00Low
10/24/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$235.00 ➝ $220.00Low
10/11/2023Evercore ISILower Target$235.00 ➝ $225.00Low
9/25/2023TD CowenLower TargetMarket Perform ➝ Market Perform$212.00 ➝ $209.00Low
9/22/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$280.00 ➝ $275.00Low
9/22/2023GuggenheimLower TargetBuy ➝ Buy$255.00 ➝ $225.00Low
9/22/2023Robert W. BairdLower TargetOutperform ➝ Outperform$267.00 ➝ $256.00Low
9/22/2023Bank of AmericaLower Target$245.00 ➝ $230.00Low
9/13/2023TD CowenInitiated CoverageMarket Perform$212.00Low
8/10/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$225.00 ➝ $250.00Low
8/10/2023Bank of AmericaBoost TargetBuy ➝ Buy$235.00 ➝ $245.00Low
7/10/2023CitigroupDowngradeBuy ➝ Neutral$260.00 ➝ $225.00Low
5/12/2023Deutsche Bank AktiengesellschaftLower Target$260.00 ➝ $250.00Low
5/12/2023Wells Fargo & CompanyLower Target$290.00 ➝ $280.00Low
5/12/2023Credit Suisse GroupLower Target$260.00 ➝ $255.00Low
3/28/2023Jefferies Financial GroupLower TargetHold$233.00 ➝ $203.00Low
2/23/2023Morgan StanleyLower TargetEqual Weight$241.00 ➝ $230.00Low
2/23/2023Credit Suisse GroupLower TargetOutperform$280.00 ➝ $260.00Low
2/23/2023CitigroupLower TargetBuy$280.00 ➝ $260.00Low
2/23/2023GuggenheimUpgradeNeutral ➝ Buy$255.00Low
1/12/2023Jefferies Financial GroupDowngradeBuy ➝ HoldLow
1/11/2023Robert W. BairdBoost TargetOutperform$275.00 ➝ $285.00Low
11/3/2022JPMorgan Chase & Co.Lower TargetOverweight$280.00 ➝ $275.00Low
11/3/2022Morgan StanleyLower TargetEqual Weight$250.00 ➝ $241.00Low
11/3/2022Credit Suisse GroupLower TargetOutperform$285.00 ➝ $280.00Low
11/2/2022William BlairReiterated RatingOutperformLow
9/29/2022Jefferies Financial GroupUpgradeHold ➝ Buy$240.00Low
8/24/2022Credit Suisse GroupInitiated CoverageOutperform$285.00Low
8/16/2022Wells Fargo & CompanyLower TargetOverweight$325.00 ➝ $300.00Low
8/9/2022Evercore ISILower Target$260.00N/A
8/9/2022CitigroupLower Target$280.00N/A
8/8/2022Deutsche Bank AktiengesellschaftLower Target$290.00 ➝ $270.00Low
8/4/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$350.00 ➝ $250.00Low
7/14/2022Deutsche Bank AktiengesellschaftLower TargetBuy$350.00 ➝ $290.00N/A
6/20/2022StephensSet Target$315.00Low
5/23/2022GuggenheimInitiated CoverageNeutralHigh
5/5/2022KeyCorpLower Target$390.00 ➝ $300.00High
4/25/2022Wells Fargo & CompanyLower TargetOverweight$390.00 ➝ $325.00High
4/25/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$370.00 ➝ $280.00High
4/6/2022StephensInitiated CoverageOverweight$377.00High
2/17/2022Bank of AmericaLower TargetBuy$445.00 ➝ $400.00High
2/17/2022UBS GroupLower TargetBuy$465.00 ➝ $420.00High
2/17/2022Morgan StanleyLower TargetOverweight$465.00 ➝ $430.00High
2/17/2022Wells Fargo & CompanyLower Target$450.00 ➝ $390.00High
2/17/2022Deutsche Bank AktiengesellschaftLower TargetBuy$409.00 ➝ $350.00High
2/17/2022CitigroupUpgradeNeutral ➝ Buy$400.00High
2/17/2022KeyCorpLower TargetOverweight$450.00 ➝ $390.00High
12/20/2021Robert W. BairdReiterated RatingBuyHigh
11/16/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$354.00 ➝ $409.00Medium
11/12/2021Robert W. BairdReiterated RatingBuy$452.00Low
11/4/2021Morgan StanleyLower TargetOverweight$480.00 ➝ $465.00Low
11/4/2021CitigroupLower TargetNeutral$425.00 ➝ $400.00High
10/14/2021Evercore ISIReiterated RatingBuyMedium
8/23/2021ArgusBoost TargetBuy$390.00 ➝ $480.00Medium
8/17/2021UBS GroupBoost TargetBuy$390.00 ➝ $465.00Low
8/5/2021Credit Suisse GroupBoost TargetNeutral$385.00 ➝ $420.00Medium
8/5/2021Wells Fargo & CompanyBoost TargetOverweight$375.00 ➝ $470.00Medium
8/5/2021Robert W. BairdBoost TargetOutperform$410.00 ➝ $461.00Medium
7/20/2021Credit Suisse GroupBoost TargetNeutral$352.00 ➝ $385.00High
5/31/2021Robert W. BairdReiterated RatingBuyMedium
5/28/2021Credit Suisse GroupBoost TargetNeutral$342.00 ➝ $352.00Low
5/28/2021JPMorgan Chase & Co.Boost TargetPositive ➝ Overweight$375.00 ➝ $390.00Medium
5/28/2021CitigroupBoost TargetNeutral$350.00 ➝ $355.00Medium
5/25/2021Truist FinancialBoost TargetBuy$324.00 ➝ $369.00Medium
5/14/2021KeyCorpBoost TargetOverweight$340.00 ➝ $360.00High
5/5/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$334.00 ➝ $354.00Medium
5/5/2021Robert W. BairdBoost TargetOutperform$338.00 ➝ $400.00Medium
2/25/2021Morgan StanleyBoost TargetOverweight$280.00 ➝ $350.00Medium
2/18/2021Truist FinancialBoost Target$256.00 ➝ $324.00Medium
2/18/2021Credit Suisse GroupBoost TargetNeutral$259.00 ➝ $301.00High
2/18/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$250.00 ➝ $334.00High
12/22/2020ArgusBoost TargetBuy$235.00 ➝ $265.00Low
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ NeutralLow
11/24/2020KeyCorpBoost TargetOverweight$233.00 ➝ $256.00High
11/3/2020Truist FinancialBoost Target$237.00 ➝ $256.00Low
10/30/2020Morgan StanleyBoost TargetOverweight$245.00 ➝ $260.00Medium
10/30/2020Deutsche Bank AktiengesellschaftBoost TargetBuy$235.00 ➝ $250.00Medium
9/14/2020ArgusBoost TargetBuy$190.00 ➝ $235.00Low
9/10/2020Jefferies Financial GroupUpgradeHold ➝ Buy$213.00 ➝ $254.00High
8/18/2020KeyCorpBoost TargetOverweight$186.00 ➝ $233.00Low
8/6/2020Morgan StanleyBoost TargetOverweight$175.00 ➝ $245.00Low
8/6/2020CitigroupBoost TargetBuy$190.00 ➝ $255.00Low
7/21/2020UBS GroupBoost TargetBuy$200.00 ➝ $236.00Low
7/1/2020Bank of AmericaUpgradeNeutral ➝ Buy$192.00Low
5/26/2020ArgusBoost TargetAverage ➝ Buy$150.00 ➝ $190.00Medium
5/13/2020UBS GroupUpgradeNeutral ➝ Buy$177.00 ➝ $200.00Low
5/12/2020Deutsche Bank AktiengesellschaftLower TargetBuy$190.00 ➝ $174.00Medium
5/8/2020JPMorgan Chase & Co.Boost TargetOverweight$160.00 ➝ $180.00Low
5/8/2020Robert W. BairdBoost TargetOutperform$156.00 ➝ $175.00Low
5/8/2020Credit Suisse GroupLower TargetNeutral$162.00 ➝ $159.00Low
5/8/2020Morgan StanleyBoost TargetOverweight$152.00 ➝ $175.00Medium
5/8/2020CitigroupBoost TargetBuy$165.00 ➝ $190.00Medium
5/8/2020SunTrust BanksBoost TargetBuy$130.00 ➝ $194.00Medium
4/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$139.00High
4/9/2020CitigroupLower TargetBuy$200.00 ➝ $165.00Medium
4/6/2020SunTrust BanksBoost TargetBuy$124.00 ➝ $130.00High
3/30/2020Wells Fargo & CompanyLower TargetOverweight$200.00 ➝ $145.00High
3/27/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$152.00High
3/26/2020BarclaysLower TargetEqual Weight$170.00 ➝ $154.00High
3/23/2020Jefferies Financial GroupLower TargetBuy$200.00 ➝ $139.00Medium
3/17/2020SunTrust BanksLower TargetBuy$188.00 ➝ $124.00High
3/2/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy$190.00High
2/18/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$169.00 ➝ $203.00Low
2/12/2020Morgan StanleyBoost TargetEqual Weight$156.00 ➝ $176.00Medium
2/12/2020Robert W. BairdReiterated RatingOutperform$165.00 ➝ $185.00Medium
2/12/2020BarclaysReiterated RatingHold$170.00Low
2/12/2020CitigroupBoost TargetBuy$185.00 ➝ $200.00Low
2/11/2020CfraBoost TargetStrong-Buy$165.00 ➝ $180.00Medium
1/10/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$143.00 ➝ $179.00Low
1/7/2020Wells Fargo & CompanyInitiated CoverageOverweight$180.00Low
1/6/2020CitigroupInitiated CoverageBuy$185.00Low
12/17/2019Robert W. BairdBoost TargetOutperform$160.00 ➝ $165.00Medium
12/9/2019KeyCorpBoost TargetOverweight ➝ Overweight$151.00 ➝ $162.00Medium
11/19/2019ArgusReiterated RatingBuy$170.00Low
10/18/2019Bank of AmericaDowngradeBuy ➝ Neutral$150.00High
9/16/2019SunTrust BanksBoost TargetBuy ➝ Buy$156.00 ➝ $162.00Medium
9/13/2019Credit Suisse GroupSet TargetHold$138.00Medium
(Data available from 6/19/2019 forward)

News Sentiment Rating

1.07 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 14 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
  • 24 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 30 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 17 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 22 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 21 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 21 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Charles River Laboratories International logo
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Read More

Today's Range

Now: $209.72
Low: $207.17
High: $211.45

50 Day Range

MA: $225.51
Low: $207.93
High: $257.24

52 Week Range

Now: $209.72
Low: $161.65
High: $275.00


336,121 shs

Average Volume

548,783 shs

Market Capitalization

$10.80 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Argus, Bank of America Co., Citigroup Inc., Evercore ISI, Guggenheim, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Robert W. Baird,, TD Cowen, The Goldman Sachs Group, Inc., TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for CRL.

What is the current price target for Charles River Laboratories International?

13 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $256.38, suggesting a possible upside of 22.3%. UBS Group AG has the highest price target set, predicting CRL will reach $290.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $205.00 for Charles River Laboratories International in the next year.
View the latest price targets for CRL.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 5 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CRL.

What other companies compete with Charles River Laboratories International?

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is (781) 222-6000 and its investor relations email address is [email protected]. The official website for Charles River Laboratories International is Learn More about contacing Charles River Laboratories International investor relations.